Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Peter O'Gorman, Jacob Laubach, Ruth Clifford, Clifton Mo, Senthil Kumar, Omar Nadeem, Monique Hartley-Brown, Siobhan Glavey, Shonali Midha, Yuxin Liu, Maja Vase, Keith Pratz, Patrick Hayden, Jessica Liegel, Paul Dowling, Emily Benjamin, Vicky Donachie, Zahra Beers, Olivia McLoughlin, Layla Horwitz, Jacinta Marron, Emma Sueiro, Marc Nolan, David Poretsky, Anna Shevlin, Sarah Beaton, Charlotte Prior, Catherine Piper, Bindu Krishnanivas, Emily Simpson, Elizabeth Karimi, Marissa Davis, Lourdes McAlester, Alanna Allen, Paul Richardson
Institutions: Mater Misericordiae University Hospital, Cancer Trials Ireland, Harvard University, Dana-Farber Cancer Institute, University Hospital Limerick, University Hospital Waterford, Royal College of Surgeons in Ireland, Aarhus University Hospital, St. James's Hospital, Beth Israel Deaconess Medical Center, National University of Ireland, Maynooth
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417009463
Cites:
Cited by:
Related to: